Navigation Links
BioMarin Announces FDA Approval for Kuvan
Date:12/13/2007

First Specific Drug Therapy Approved for the Treatment of PKU

NOVATO, Calif., Dec. 13 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Kuvan(TM) (sapropterin dihydrochloride) Tablets, the first specific drug therapy approved for the treatment of phenylketonuria (PKU). Shipments to the distribution channel will commence tomorrow, and BioMarin will begin promotion of Kuvan immediately.

"The approval of Kuvan represents an important milestone for PKU patients and their families and also for BioMarin. We are extremely pleased to bring this promising treatment option to market in just a little over three years since the IND filing, and we are now ready for an immediate launch," said Jean-Jacques Bienaime, Chief Executive Officer of BioMarin. "We would like to thank all the patients, their families and physicians, our corporate partners, the FDA, and BioMarin employees for their hard work and dedication in making Kuvan a reality."

"In clinical trials, Kuvan has been shown to help control blood Phe levels in PKU patients, and I am thrilled that this new therapy is now commercially available to the PKU community," stated Dr. Barbara Burton, Professor of Pediatrics, Northwestern University Feinberg School of Medicine; Director, PKU Clinic at Children's Memorial Hospital; and Clinical Investigator in the Kuvan Phase 2 and Phase 3 trials. "With Kuvan now approved, physicians and patients have, for the first time, a drug therapy option to manage the disease."

Kuvan is indicated to reduce blood phenylalanine (Phe) levels in patients with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin (BH4) responsive PKU and is to be used in conjunction with a Phe-restricted diet. To determine if there is a response to Kuvan, the recommended starting dose of Kuvan is 10 mg/kg/day taken once daily for up to a month. If there
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... According to a new market research report " Sterilization ... Filtration, E-beam, Gamma), Services (Onsite & Offsite), Consumables (Indicators, Detergents, ... 2020", published by MarketsandMarkets, The Sterilization Equipment Market is expected ... CAGR of 7.6%.from 2015 to 2020. Browse ... and 37 F igures spread ...
(Date:7/31/2015)... July 31, 2015 Egalet Corporation (Nasdaq: ... pharmaceutical company focused on developing, manufacturing and marketing ... its previously announced underwritten public offering of 7,666,667 ... offering price of $11.25 per share. The shares ... shares issued upon the exercise in full by ...
(Date:7/31/2015)... 2015  Xencor, Inc. (NASDAQ: XNCR ), a ... treatment of autoimmune diseases, asthma and allergic diseases, and ... Hata to its board of directors. ... development is a tremendous asset to our board," said ... officer of Xencor. "Xencor faces a range of opportunities ...
Breaking Medicine Technology:Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 2Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 3Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 4Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4Xencor Appoints Yujiro S. Hata to Board of Directors 2Xencor Appoints Yujiro S. Hata to Board of Directors 3
(Date:7/31/2015)... ... July 31, 2015 , ... Girl Scouts of Historic Georgia and Peach State ... Girl Scout "Be a Friend First" program. Representatives from Peach State Health Plan presented ... State Health Plan and our parent company, Centene Corporation, are dedicated to raising anti-bullying ...
(Date:7/31/2015)... Seattle, WA (PRWEB) , ... July 31, 2015 , ... ... rapidly transforming the way we treat aging diseases. , BioViva announces it has ... to treat patients with Alzheimer’s Disease (AD) and find a cure. MaxLife will grant ...
(Date:7/31/2015)... ... , ... The Heart Fit Clinic has increased a patient's fitness level 60 ... 150 beats versus 100 beats, this is a big deal," says Diamond Fernandes, director ... to patients with heart disease," he adds. People with angina are able to do ...
(Date:7/31/2015)... York, NY (PRWEB) , ... July 31, 2015 , ... ... kidney disease, according to a study published today in Nature Communications and led by ... conducted in mice, suggests that variations in the gene RTN1 led to greater production ...
(Date:7/31/2015)... ... , ... Indosoft, Inc., is pleased to announce a major update to its ... contact center ACD system for Asterisk-based call centers . The new features make ... to the agent only when wanted, and allows for validation of data as the ...
Breaking Medicine News(10 mins):Health News:Peach State Health Plan Presents $10,000 Check for “Be a Friend First” Anti-Bullying Program to Local Girl Scouts 2Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 2Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 3Health News:Heart Fit Clinic Helps Patient Increase Fitness Level with External Counterpulsation 2Health News:Mount Sinai Researchers Find Key Gene Drives Kidney Disease Severity 2Health News:Mount Sinai Researchers Find Key Gene Drives Kidney Disease Severity 3Health News:Q-Suite 5.9 Adds Validation Tools to Call Center Software Agent Screen 2
... has issued a warning to leave no stone unturned to ... health department found, nearly 20%// of the children under 12 ... snacks on a daily basis. Healthy options like fruits ... ,The Health Minister, John Hill, said "We're working with ...
... New research has been released by Australian obesity experts that ... the international conference on obesity in Sydney there were three ... cent reduction in mortality rates in obese people who had ... around the upper part of the stomach for the procedure ...
... A team of surgeons at Children's National Medical Centre ... conjoined twins who shared a spinal cord and were// ... reported that Mateo and McHale Shaw from Sheboygan, Wisconsin ... 12 hours into Wednesday night. The hospital authorities had ...
... that men have a 4- to 5-point IQ advantage over ... on 100,000 17- to 18-year-//olds on the Scholastic Assessment Test ... is not obvious because girls mature faster than boys. This ... years. ,145 items from the SAT were examined ...
... is not rude but on the contrary would improve concentration.// ... Stirling in Scotland, led by Gwyneth Doherty-Sneddon have concluded in ... British Journal of Developmental Psychology, that looking away or gazing ... ,In the study that was conducted on a ...
... a week might reduce the risk of heart disease significantly.// ... Cardiology stated that as little as two servings of eight grams ... reduce the risk of heart disease by as much as 11%. ... the same kinds of nuts five days a week only results ...
Cached Medicine News:Health News:Successfully Separated Conjoined Twins In A Critical Yet Stable Condition 2Health News:Greater g factor in men responsible for sex differences in general mental ability 2Health News:Greater g factor in men responsible for sex differences in general mental ability 3
The Auto Suture™ EEA™ 34mm reusable stainless steel sizer has application in intestinal, colorectal and esophageal surgery to help evaluate the diameter of tubular structures....
... synthesized in the parafollicular C-cells of the ... granules. The major action of calcitonin is ... osteoclast activity, resulting in decreased mobilization of ... most evident in conditions associated with high ...
Validated by decades of research and clinical experience, HFA is the accepted standard of care in glaucoma diagnosis and management. With HFA you can feel confident you're providing the best possible...
Erbium Laser with Sapphire Erbium Handpiece for Dermatological and Cosmetic Surgery...
Medicine Products: